tradingkey.logo

Chemomab Therapeutics Ltd

CMMB
查看詳細走勢圖
1.530USD
+0.080+5.52%
收盤 02/06, 16:00美東報價延遲15分鐘
37.68M總市值
虧損本益比TTM

Chemomab Therapeutics Ltd

1.530
+0.080+5.52%
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

+5.52%

5天

-1.27%

1月

-14.98%

6月

-60.56%

今年開始到現在

-7.25%

1年

-80.68%

查看詳細走勢圖

TradingKey 股票評分

由於缺少必要的數據,暫時無法對該公司進行評分

Chemomab Therapeutics Ltd新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

Chemomab Therapeutics Ltd簡介

Chemomab Therapeutics Ltd (formerly known as Anchiano Therapeutics Ltd) is a Israel-based clinical-stage biopharmaceutical company. The Company specializes in the development of patient oriented targeted therapy for the treatment of a wide range of fibrotic and inflammatory diseases with high unmet medical need among others. Its therapeutic and diagnostic technology, BC-819, constitutes a search paradigm for the targeted destruction of cancer cells with no effect on surrounding tissue and no observed side effects for long-term, safe treatment and prevention of cancer. The patient oriented targeted therapy approach is based on the identification of particular genes that are expressed only in tumors.
公司代碼CMMB
公司Chemomab Therapeutics Ltd
CEOMor (Adi)
網址https://www.chemomab.com/
KeyAI